A. Partisano

Safety and efficacy of upfront plerixafor + G‐CSF versus placebo + G‐CSF for mobilization of CD34+ hematopoietic progenitor cells in patients ≥60 and <60 years of age with non‐Hodgkin's lymphoma or multiple myeloma

A. Nademanee, J. Dipersio, P. Stiff, 2013, American journal of hematology.

A clinical review of montelukast in the treatment of seasonal allergic rhinitis

M. Gonyeau, A. Partisano, 2003 .

Fitusiran, an Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia: Updated Results from a Phase 1 and Phase 1/2 Extension Study in Patients without Inhibitors

A. Akinc, D. Bevan, K. Pasi, 2016 .

A Subcutaneously Administered Investigational RNAi Therapeutic (ALN-CC5) Targeting Complement C5 for Treatment of PNH and Complement-Mediated Diseases: Preliminary Phase 1/2 Study Results in Patients with PNH

A. Borodovsky, N. Najafian, Jae B. Kim, 2016 .

Abstracts from the First European Meeting for ATTR Amyloidosis for Doctors and Patients

M. Sweetser, J. Gollob, I. Conceição, 2017, Orphanet Journal of Rare Diseases.

PHASE 2 OPEN-LABEL EXTENSION (OLE) STUDY OF PATISIRAN, AN INVESTIGATIONAL RNA INTERFERENCE (RNAI) THERAPEUTIC FOR THE TREATMENT OF HEREDITARY ATTR AMYLOIDOSIS WITH POLYNEUROPATHY

J. Gollob, H. Schmidt, M. Polydefkis, 2017 .